Revenue Growth
Consolidated net sales increased 27% year‑over‑year to $50.2 million, driven by strength in international medical exports and Canadian branded sales.
We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The earnings call conveyed a largely positive operating and financial performance: robust revenue growth (+27% YoY), record international export sales (+171% YoY), strong adjusted EBITDA expansion (+118% YoY) and return to net income, supported by strategic EU‑GMP capacity and brand strength in Canada. Headwinds were primarily cash flow timing and one‑time tax payments, modest operational delays in the Netherlands awaiting certification, industry price normalization in some markets, and regulatory uncertainty around U.S. rescheduling. Management presented these challenges as manageable and temporary while emphasizing disciplined capital allocation and continued expansion, indicating confidence in sustainable profitable growth.
Management guided to a stronger back half of fiscal 2026 as Delta 2 (first harvest the week of May 18; initial sales late Q2/early Q3) ramps toward 40 metric tons of annual capacity by mid‑next year (a 33% increase in B.C. production vs. FY25, with ~15 metric tons incremental this year) and Groningen Phase 2 is expected to commence operations before the end of Q2, with plans to enter multiple new jurisdictions and expand non‑flower form factors; they also expect pricing for EU‑GMP flower (notably in Germany) to remain relatively stable. Village Farms expects to return to positive consolidated cash flow in Q2 and sustain it through the remainder of the year, supporting an increase in cash from Q1’s ~$56M (restricted $5M; net cash ~$20M) despite Q1 cash impacts including CAD 16.4M ($12.1M) of Canadian income tax, $15.9M of excise taxes, $9.2M of capex and $6.4M of share repurchases (total debt $36M); the guidance is supported by Q1 trends of consolidated net sales up 27% to $50.2M, international export sales near $15M (↑171% YoY, ↑60% sequential), consolidated adjusted EBITDA $9.9M (+118%, 20% margin), cannabis adjusted EBITDA $10.2M (+48%, 20.5% margin) and cannabis gross margin 43% (above the 30–40% target), with a stated line of sight to continued profitable growth through 2027.
Consolidated net sales increased 27% year‑over‑year to $50.2 million, driven by strength in international medical exports and Canadian branded sales.
Consolidated adjusted EBITDA from continuing operations rose 118% year‑over‑year to $9.9 million, lifting adjusted EBITDA margin to 20% from 11.4% in the prior‑year quarter.
Consolidated net income from continuing operations was $2.7 million ($0.03 per share) versus a net loss of $2.1 million in Q1 last year, marking the fourth consecutive quarter of positive net income.
International export sales nearly tripled year‑over‑year, increasing 171% to a record of nearly $15 million and growing 60% sequentially, with Germany a primary driver.
Cannabis gross margin rose to 43% from 39% a year ago, staying above the company's 30%–40% target range, supported by higher international export mix and Netherlands contribution.
Cannabis segment adjusted EBITDA improved 48% to $10.2 million (20.5% margin) versus $6.9 million a year ago, reflecting favorable product mix and international sales.
Completed major EU‑GMP production upgrades in British Columbia (company believes it now operates the world's largest EU‑GMP certified cannabis facility). Began planting at Delta 2 expansion (adds ~40 MT annual capacity at full ramp; ~15 MT incremental this year). Groningen Phase 2 construction completed; awaiting final certification to begin operations.
Maintained a top‑5 overall share in Canada's adult‑use market and #1 share in dried flower. Pure Sunfarms achieved 15 consecutive months of flower market share gains; branded sales up ~5% year‑over‑year.
Ended Q1 with approximately $56 million cash (including $5 million restricted) and a stated net cash position of $20 million. Total debt $36 million. Completed share repurchases of over 2 million shares at $6.4 million in Q1 (Board‑approved buyback subsequently completed). Amended and extended Farm Credit Canada loan with improved rate and maturity to Feb 2031.
Good morning, ladies and gentlemen. Welcome to Village Farms International's First Quarter 2026 Financial Results Conference Call. This morning, Village Farms issued a news release reporting its Financial Results for the first quarter ended March 31, 2026. That news release, along with the company's financial statements, are available on the company's website at villagefarms.com under the Investors heading. Please note that today's call is being broadcast live over the Internet and will be archived for replay both by telephone and via the Internet beginning approximately 1 hour following completion of the call. Details of how to access the replays are available in today's news release. Before we begin, let me remind you that forward-looking statements may be made today during or after the formal part of this conference call. Certain material assumptions were applied in providing these statements, many of which are beyond our control.
These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. A summary of these underlying assumptions, risks, uncertainties is contained in the company's various securities filings with the SEC and Canadian regulators, including its Form 10-K MD&A for the year ended December 31, 2025, and 10-Q for the quarter ended March 31, 2026, which will be available on EDGAR and SEDAR+. These forward-looking statements are made as of today's date, and except as required by applicable securities law, we undertake no obligation to publ...
May 11th, 2026
March 12th, 2026
November 10th, 2025
August 11th, 2025
May 12th, 2025
March 13th, 2025
November 7th, 2024
August 8th, 2024
May 8th, 2024
March 13th, 2024
November 8th, 2023
August 9th, 2023
May 10th, 2023